BCL2 and B-cell chronic lymphocytic leukemia: Idelalisib, an oral PI3K inhibitor, was approved by NICE for use in patients with CLL in combination with rituximab in 2015 [15], and venetoclax, an oral Bcl‐2 inhibitor, gained NICE approval for use in patients with CLL in October 2017 [16].